


Iridium-Catalyzed Intramolecular Oxidative Cyclization of Alkenyl Amides and Alkenoic Acids

Midori Nagamoto
Takahiro Nishimura*¹ 
Hideki Yorimitsu

Department of Chemistry, Graduate School of Science,
Kyoto University, Sakyo, Kyoto 606-8502, Japan
tnishi@sci.osaka-cu.ac.jp

Published as part of the Special Topic *Modern Cyclization
Strategies in Synthesis*



Received: 31.03.2017
Accepted after revision: 02.05.2017
Published online: 13.06.2017
DOI: 10.1055/s-0036-1588435; Art ID: ss-2017-c0211-st

Abstract An iridium/dppf complex efficiently catalyzed the oxidative cyclization of *N*-sulfonyl alkenyl amides and alkenoic acids. Electron-deficient alkenes were effective as sacrificial hydrogen acceptors. High selectivity of the oxidative cyclization over the competing addition reaction has been realized by the use of NaI as an additive.

Key words iridium, oxidative functionalization, alkenes, amides, carboxylic acids

Direct functionalization of readily available alkenes has attracted considerable attention from the aspect of atom and step economy. Additions of heteroatom nucleophiles to alkenes² are an important class of transformations as they afford highly valuable building blocks such as enamines and vinyl ethers as a result of oxidative functionalization,^{3–7} or alkylamines and ethers as a consequence of the formal addition of heteroatom–hydrogen bond.⁸ Late transition-metal catalysts have contributed much to the development of efficient protocols for oxidative functionalization.^{3–6} In particular, there have been numerous reports on palladium catalysis: Wacker-type oxidation,^{2a,b,e,3} which involves β -hydride elimination as a key step, has been successfully extended to oxidative functionalization of alkenes with various nucleophiles to form carbon–heteroatom bonds. Rhodium complexes have also been studied as versatile catalysts for functionalization of alkenes.⁴ Jiménez, Pérez-Torrente, and co-workers reported that cationic rhodium complexes containing flexible hemilabile phosphine ligands exhibit high catalytic activity toward *anti*-Markovnikov oxidative amination.^{4d–f} Copper-catalyzed oxidative amination reactions via radical mechanism have also been reported.⁵

Recently we studied iridium-catalyzed hydrofunctionalization reactions of alkenes such as asymmetric cyclization of alkenoic acids and *N*-sulfonyl alkenyl amides leading to chiral γ -lactones and γ -lactams.⁹ Although iridium complexes have emerged as effective catalysts for hydrofunctionalization of alkenes,¹⁰ there have been only few reports on oxidative functionalization with heteroatom nucleophiles. Hartwig and co-workers reported iridium-catalyzed amination and etherification of aliphatic alkenes, where oxidative functionalization was competitive with hydrofunctionalization.^{10e,f} Herein, we report the iridium-catalyzed intramolecular oxidative functionalization of alkenes with *N*-sulfonyl amides and carboxylic acids.

Treatment of *N*-tosyl-2,2-diphenyl-4-pentenamide (**1a**) in the presence of [IrCl(coe)₂]₂ (5 mol% of Ir, coe = cyclooctene) and a bisphosphine ligand (5 mol%) in toluene at 100 °C for 3 hours gave the corresponding cyclization products as a mixture of oxidative amination product **2a** and hydroamination product **3a**, along with **4a** formed by hydrogenation of **1a** (Table 1). The reaction in the presence of an iridium/dppe complex gave hydroamination product **3a** predominantly in low yield (Table 1, entry 1). Dppb and dppf complexes exhibited higher catalytic activity toward cyclization and increased the ratio of oxidative amination product **2a** to 28% and 45%, respectively (entries 2 and 3). By using xantphos, the selectivity of **2a** was improved but the yield of cyclization products was only 12% (entry 4). Norbornene (**A1**) and 3,3-dimethylbut-1-ene (**A2**) were ineffective to decrease the undesirable formation of **4a**, although they have been used as sacrificial hydrogen acceptors for several iridium-catalyzed dehydrogenative functionalization reactions (entries 5 and 6).¹¹ In contrast, electron-deficient alkenes such as ethyl acrylate (**A3**) and methyl vinyl ketone (MVK, **A4**) successfully suppressed the formation of **4a** (entries 7 and 8). Surprisingly, the reaction

in the presence of NaI (50 mol%) dramatically improved the selectivity of **2a** by up to 97% (entry 9). KI and *n*-Bu₄NI had little effect on the selectivity (entries 10 and 11).

Table 1 Screening Conditions^a

Entry	Ligand	Hydrogen acceptor	Additive	Yield (%) 2a + 3a	2a/3a	Yield (%) 4a
1	dppe	–	–	15	3/97	0
2	dppb	–	–	66	28/72	17
3	dppf	–	–	62	45/55	24
4	xantphos	–	–	12	73/27	5
5	dppf	A1	–	70	53/47	18
6	dppf	A2	–	68	51/49	21
7	dppf	A3	–	88	70/30	0
8	dppf	A4	–	66	82/18	0
9	dppf	A4	NaI	99 (92) ^b	97/3	0
10	dppf	A4	KI	54	86/14	0
11	dppf	A4	<i>n</i> -Bu ₄ NI	83	88/12	0

^a Reaction conditions: **1a** (0.10 mmol), [IrCl(coe)₂]₂ (5 mol% Ir), ligand (5 mol%), hydrogen acceptor (3 equiv), and additive (50 mol%) in toluene (0.40 mL) at 100 °C for 3 h.

^b Isolated yield in parentheses.

The results obtained for the iridium-catalyzed oxidative cyclization of *N*-sulfonyl alkenyl amides are summarized in Table 2. Amides **1b–e** bearing aryl, *n*-hexyl, and benzyl groups participated in the reaction to give **2b–e** in high yields with high selectivity (Table 2, entries 1–4). The reactions of **1f** and **1g** bearing sterically less bulky cyclic pentamethylene and dimethyl groups proceeded at 120 °C to give the corresponding cyclization products in good yields (entries 5 and 6). Unsubstituted pentenamide **1h** participated in the reaction at 135 °C to give **2h'** in 27% yield (entry 7). In the reaction of amide **1i**, which bears both a terminal- and an internal alkene moiety, cyclization occurred only at the terminal alkene (entry 8). Not only *N*-tosylamides but also *N*-mesylamide **1j** reacted to give the cy-

Table 2 Oxidative Cyclization of Alkenyl Amides^a

Entry	R ¹ , R ²	Yield (%) 2 + 3	2/3
1	R ¹ = R ² = 4-MeOC ₆ H ₄ (1b)	89	91/9
2 ^b	R ¹ = R ² = 4-ClC ₆ H ₄ (1c)	92	95/5
3 ^b	R ¹ = R ² = <i>n</i> -hexyl (1d)	81	>99/1
4	R ¹ = R ² = benzyl (1e)	89	97/3
5 ^c	R ¹ = R ² = -(CH ₂) ₅ - (1f)	72	99/1 ^d
6 ^c	R ¹ = R ² = Me (1g)	81	97/3 ^e
7 ^f	R ¹ = R ² = H (1h)	27	92/8 ^g
8	R ¹ = Ph, R ² = cinnamyl (1i)	83	98/2
9 ^h	R ¹ = R ² = Ph (1j)	95	97/3

^a Reaction conditions: **1** (0.20 mmol), [IrCl(coe)₂]₂ (5 mol% Ir), dppf (5 mol%), MVK (3 equiv), and NaI (50 mol%) in toluene (0.80 mL) at 100 °C for 3 h.

^b At 80 °C for 6 h.

^c Ethyl vinyl ketone instead of MVK in *p*-xylene at 120 °C for 12 h.

^d **2f/2f'** = 23:77.

^e **2g/2g'** = 24:76.


^f Ethyl vinyl ketone instead of MVK in *p*-xylene at 135 °C for 12 h.

^g **2h/2h'** = 0:100.

^h *N*-Mesylamide instead of *N*-tosylamide.

clization products in 95% yield with 97% selectivity of **2j** (entry 9).

Allylamines can be transformed into imidazolidinone derivatives by a one-pot operation. Treatment of allylamines with tosyl isocyanate gave the corresponding *N*-allyl-*N'*-tosylureas, which were subjected to the present catalytic conditions without purification to give the cyclization products. It was found that allylic substituents had a significant effect on the selectivity of the reaction (Table 3). The reaction of an alkenyl urea generated from allylamine (**5a**) gave the cyclization product in moderate yield with 96% selectivity of **7a** (Table 3, entry 1). However, the reaction of allylamine **5b** bearing a methyl group at the allylic position gave the cyclization product as a mixture of **7b** and **8b** in a ratio of 12:88 (entry 2). A sterically bulky cyclohexyl group in **5c** completely suppressed the formation of **7c** and the hydroamination product **8c** was obtained in high yield (entry 3). These results indicate that β-hydride elimination leading to the oxidative cyclization product is inhibited by the steric repulsion between the allylic substituents and the iridium center.

Table 3 Cyclization of Alkenyl Ureas In Situ Generated from Allyl-amines^a


Entry	R	Yield (%) 7 + 8	7/8
1	H (5a)	66	96/4 ^b
2	Me (5b)	78	12/88
3	Cy (5c)	86	<1/99

^a Reaction conditions for urea formation: **5** (0.20 mmol) and TsNCO (0.21 mmol) in CH₂Cl₂ (0.50 mL) at r.t. for 2 h. Reaction conditions for iridium-catalyzed cyclization: [IrCl(coe)₂]₂ (5 mol% Ir), dppf (5 mol%), MVK (3 equiv), and NaI (50 mol%) in toluene (0.80 mL) at 100 °C for 3 h.
^b **7a/7a'** = 10/90.

The same catalyst system can also be applied to the cyclization of alkenoic acids leading to γ -lactones (Table 4). The reactions of alkenoic acids **9a–e** bearing electron-rich and electron-poor aryl groups gave the cyclization products in high yields with over 97% selectivity of **10a–e** (Table 4, entries 1–5). Alkyl-substituted alkenoic acids **9f** and **9g** also participated in the reaction to give **10f** and **10g**, respectively, with high selectivity (entries 6 and 7). The internal alkene moiety in **9h** did not participate in the reaction (entry 8). A methyl group at β -position in **9i** slightly decreased the selectivity of oxidative cyclization (entry 9).

Hartwig and co-workers reported an iridium-catalyzed addition of benzamides to alkenes,^{10e} where it was proposed that the reaction proceeds via N–H oxidative addition and alkene insertion into the Ir–N bond of the resulting amidoiridium(III) species. The formation of a hydrido-iridium(III) carboxylate via oxidative addition of carboxylic acid was also confirmed by Mashima and co-workers.¹² Thus, the present reaction might involve oxidative addition of acidic N–H and O–H bonds as the first step. A stoichiometric reaction of [IrCl(coe)₂]₂, dppf, and **1h** in benzene-*d*₆ at room temperature resulted in the formation of hydrido-iridium(III) complexes as a mixture of five isomers. These hydrido-iridium(III) species showed double doublet or virtual triplet peaks at $\delta = -22.4, -23.7, -27.4, -27.7,$ and -29.5 in the ¹H NMR spectra, which were assigned to the hydrides at the *cis*-position to two phosphorous atoms.

A plausible catalytic cycle of the present reaction is shown in Scheme 1. Oxidative addition of amide **1a** to the iridium/dppf complex **A** generates hydrido-iridium(III) species **B**, and alkene insertion into the Ir–N bond generates alkylhydrido-iridium(III) species **C**.¹³ One possible pathway involves elimination of HX from the intermediate **C** to form

Table 4 Oxidative Cyclization of Alkenoic Acids^a

Entry	R ¹ –R ³	Yield (%) 10 + 11	10/11
1	R ¹ = R ² = Ph, R ³ = H (9a)	95	97/3
2	R ¹ = R ² = 4-MeC ₆ H ₄ , R ³ = H (9b)	95	98/2
3	R ¹ = R ² = 4-MeOC ₆ H ₄ , R ³ = H (9c)	93	99/1
4	R ¹ = R ² = 4-FC ₆ H ₄ , R ³ = H (9d)	90	98/2
5 ^b	R ¹ = R ² = 4-ClC ₆ H ₄ , R ³ = H (9e)	90	98/2
6	R ¹ = R ² = Bn, R ³ = H (9f)	83	99/1
7 ^c	R ¹ = R ² = Me, R ³ = H (9g)	59	>99/1
8	R ¹ = Ph, R ² = cinnamyl, R ³ = H (9h)	91	99/1
9	R ¹ = R ² = Ph, R ³ = Me (9i)	84	90/10


^a Reaction conditions: **9** (0.20 mmol), [IrCl(coe)₂]₂ (5 mol% Ir), dppf (5 mol%), MVK (3 equiv), and NaI (50 mol%) in toluene (0.80 mL) at 100 °C for 3 h.

^b For 12 h.

^c Ethyl vinyl ketone instead of MVK in *p*-xylene at 135 °C for 12 h.


alkyliridium(I) species **D**, which undergoes β -hydride elimination to give oxidative cyclization product **2a** and hydrido-iridium(I) species **E**. The reaction of **E** with methyl vinyl ketone in the presence of HX gives ethyl methyl ketone and regenerates the iridium catalyst **A**. An alternative pathway involves β -hydride elimination from intermediate **C** to give iridium(III) dihydride **F**, and elimination of HX generates **E** which reacts with MVK. The inefficiency of norbornene and 3,3-dimethylbut-1-ene as hydrogen acceptors implies that the iridium(III) dihydride species is not likely to be directly involved in the hydrogenation of sacrificial alkenes.¹¹ Instead, the hydrogen transfer would proceed via conjugate addition of the iridium(I) hydride to electron-deficient alkenes and sequential protonation. The key role of sodium iodide might be the halide exchange on the iridium to facilitate the elimination of HX to give the iridium(I) species.

To gain further insight into the reaction mechanism, the effect of counterions of the iridium catalyst was investigated. By using [Ir(cod)]₂ as a catalyst precursor, the reaction of **1a** in the absence of NaI gave the cyclization products in 85% yield with 84% selectivity of **2a**. In contrast, the reaction in the presence of NaI (50 mol%) increased the selectivity of **2a** to 96% (Scheme 2a). These results indicate that the excess amount of iodide is essential for the high selectivity of **2**. The reaction of **1a** was also conducted in the presence of [Ir(OH)(cod)]₂ as a catalyst precursor, which is expected to react with **1a** to form an amidoiridium(I) species **G** (Scheme 2b). The cyclization products were not obtained in the absence of NaI. This result implies that alkene insertion



Scheme 1 Plausible catalytic cycle

into Ir(I)–N bond does not take place¹³ and that the amidoiridium(I) is inactive toward oxidative addition of another molecule of **1a** to form hydrido-iridium(III) species. The presence of NaI (50 mol%) prompted the reaction to give the cyclization products in 81% yield with 94% selectivity of **2a**. This is presumably because the catalytically active iodoiridium(I) species was generated from the amidoiridium(I) in the presence of excess NaI.



Scheme 2 Mechanistic studies

In summary, we have developed the oxidative cyclization of *N*-sulfonyl alkenyl amides and alkenoic acids catalyzed by an iridium/dppf complex in the presence of methyl vinyl ketone and NaI. The efficiency of electron-deficient alkenes as sacrificial hydrogen acceptors indicates that an iridium(I) hydride species is involved in the catalytic cycle. The presence of NaI was found to be important to suppress the competing addition reaction.

All anaerobic and moisture-sensitive manipulations were carried out with standard Schlenk techniques under predried N₂. NMR spectra were recorded on JEOL JNM ECA-600 spectrometer (600 MHz for ¹H and 150 MHz for ¹³C) and JEOL JNM ECZ-400 spectrometer (400 MHz

for ¹H and 100 MHz for ¹³C). Chemical shifts are reported in δ (ppm) referenced to the residual peaks of CDCl₃ (δ 7.26) for ¹H NMR, and CDCl₃ (δ 77.00) for ¹³C NMR. High-resolution mass spectra were obtained with a Bruker micrOTOF spectrometer. Preparative TLC was performed with Silica Gel 60 PF₂₅₄ (Merck).

Iridium complexes, [IrCl(cod)]₂,¹⁴ [Ir(cod)]₂,¹³ and [Ir(OH)(cod)]₂¹⁵ were prepared according to the reported procedures. Compounds **1a** (CAS: 1799905-43-3), **1f** (CAS: 1310538-68-1), **1g** (CAS: 1310538-67-0), **1h** (CAS: 413188-48-4), and **1j** (CAS: 1993425-86-7) were prepared from the corresponding carboxylic acids according to the reported procedure.¹⁶ Allyl amines **5b** (CAS: 37857-30-0) and **5c** (CAS: 1826073-73-7) were prepared according to the reported procedure.¹⁷ Compounds **9a** (CAS: 6966-03-6), **9b** (CAS: 138952-03-1), **9c** (CAS: 1803403-23-7), **9d** (CAS: 1397711-73-7), **9e** (CAS: 1803403-24-8), **9f** (CAS: 1803403-25-9), **9g** (CAS: 16386-93-9), and **9i** (CAS: 175879-58-0) were prepared according to the reported procedures.^{18,19}

N-Sulfonyl Alkenyl Amides **1**; General Procedure¹⁶

To a solution of alkenoic acid **9** (1.0 equiv) in THF (0.33 M) was added *p*-toluenesulfonyl isocyanate (1.0 equiv), and the mixture was stirred at r.t. for 10 min. To the solution was added Et₃N (1.0 equiv) and the mixture was stirred at r.t. for 6 h. Aq HCl was added to the mixture, and the resulting mixture was extracted with EtOAc (3 ×). The combined organic layers were washed with brine, dried (Na₂SO₄), filtered, and concentrated on a rotary evaporator. The residue was subjected to short column chromatography on silica gel with EtOAc/hexane (1/2) as eluent and recrystallized from EtOAc and hexane to give **1**.

2,2-Bis(4-methoxyphenyl)-*N*-tosylpent-4-enamide (**1b**)

This compound was prepared from 2,2-bis(4-methoxyphenyl)pent-4-enoic acid (**9c**, CAS: 1803403-23-7) according to the general procedure; yield: 885.4 mg (1.90 mmol, 95%); white solid.

¹H NMR (CDCl₃): δ = 7.79 (br s, 1 H), 7.75 (d, *J* = 8.2 Hz, 2 H), 7.28 (d, *J* = 8.2 Hz, 2 H), 7.04 (d, *J* = 8.9 Hz, 4 H), 6.81 (d, *J* = 8.9 Hz, 4 H), 5.51 (ddt, *J* = 16.9, 10.4, 7.0 Hz, 1 H), 4.88 (d, *J* = 10.4 Hz, 1 H), 4.86 (d, *J* = 16.9 Hz, 1 H), 3.81 (s, 6 H), 2.99 (d, *J* = 7.0 Hz, 2 H), 2.45 (s, 3 H).

¹³C NMR (CDCl₃): δ = 171.9, 158.8, 144.9, 135.1, 133.6, 132.2, 129.9, 129.4, 128.4, 118.8, 114.0, 60.2, 55.3, 42.9, 21.7.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₆H₂₈NO₅S: 466.1683; found: 466.1702.

2,2-Bis(4-chlorophenyl)-*N*-tosylpent-4-enamide (**1c**)

This compound was prepared from 2,2-bis(4-chlorophenyl)pent-4-enoic acid (**9e**, CAS: 1803403-24-8) according to the general procedure; yield: 339.2 mg (0.72 mmol, 72%); white solid.

¹H NMR (CDCl₃): δ = 7.80 (br s, 1 H), 7.75 (d, *J* = 8.1 Hz, 2 H), 7.30 (d, *J* = 8.1 Hz, 2 H), 7.26 (d, *J* = 8.1 Hz, 4 H), 7.03 (d, *J* = 8.1 Hz, 4 H), 5.47 (ddt, *J* = 17.3, 10.2, 7.0 Hz, 1 H), 4.95 (d, *J* = 10.2 Hz, 1 H), 4.91 (d, *J* = 17.3 Hz, 1 H), 3.01 (d, *J* = 7.0 Hz, 2 H), 2.46 (s, 3 H).

¹³C NMR (CDCl₃): δ = 170.4, 145.3, 138.3, 134.6, 134.0, 132.4, 130.0, 129.4, 128.9, 128.4, 120.1, 60.6, 42.5, 21.7.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₄H₂₂³⁵Cl₂NO₃S: 474.0692; found: 474.0675.

2-Allyl-2-hexyl-*N*-tosyloctanamide (**1d**)

This compound was prepared from 2-allyl-2-hexyloctanoic acid (CAS: 1803403-26-0) according to the general procedure; yield: 382.3 mg (0.91 mmol, 91%); white solid.

$^1\text{H NMR}$ (CDCl_3): δ = 8.16 (br s, 1 H), 7.93 (d, J = 8.1 Hz, 2 H), 7.32 (d, J = 8.1 Hz, 2 H), 5.53 (ddt, J = 17.0, 10.2, 7.3 Hz, 1 H), 5.05–4.99 (m, 2 H), 2.43 (s, 3 H), 2.22 (d, J = 7.3 Hz, 2 H), 1.47–1.41 (m, 2 H), 1.38–1.32 (m, 2 H), 1.26–1.19 (m, 4 H), 1.19–1.13 (m, 8 H), 1.09–1.00 (m, 2 H), 1.00–0.91 (m, 2 H), 0.86 (t, J = 7.1 Hz, 6 H).

$^{13}\text{C NMR}$ (CDCl_3): δ = 174.3, 144.9, 135.5, 132.7, 129.4, 128.5, 119.0, 50.0, 37.4, 35.1, 31.5, 29.6, 23.4, 22.5, 21.6, 14.0.

HRMS (APCI): m/z [$M + H$] $^+$ calcd for $\text{C}_{24}\text{H}_{40}\text{NO}_3\text{S}$: 422.2723; found: 422.2723.

2,2-Dibenzyl-*N*-tosylpent-4-enamide (1e)

This compound was prepared from 2,2-dibenzylpent-4-enoic acid (**9f**, CAS: 1803403-25-9) according to the general procedure; yield: 327.0 mg (0.75 mmol, 75%); white solid.

$^1\text{H NMR}$ (CDCl_3): δ = 7.92 (d, J = 8.2 Hz, 2 H), 7.81 (br s, 1 H), 7.38 (d, J = 8.2 Hz, 2 H), 7.19 (t, J = 7.5 Hz, 2 H), 7.13 (t, J = 7.5 Hz, 4 H), 6.95 (d, J = 7.5 Hz, 4 H), 5.90 (ddt, J = 17.0, 10.6, 6.8 Hz, 1 H), 5.27 (d, J = 10.6 Hz, 1 H), 5.15 (d, J = 17.0 Hz, 1 H), 3.09 (d, J = 14.0 Hz, 2 H), 2.76 (d, J = 14.0 Hz, 2 H), 2.51 (s, 3 H), 2.17 (d, J = 6.8 Hz, 2 H).

$^{13}\text{C NMR}$ (CDCl_3): δ = 173.4, 145.0, 135.9, 135.4, 132.4, 130.2, 129.4, 129.0, 128.4, 126.9, 120.4, 52.0, 42.3, 35.6, 21.7.

HRMS (APCI): m/z [$M + H$] $^+$ calcd for $\text{C}_{26}\text{H}_{28}\text{NO}_3\text{S}$: 434.1784; found: 434.1795.

(*E*)-2-Allyl-2,5-diphenyl-*N*-tosylpent-4-enamide (1i)

This compound was prepared by the reaction of (*E*)-2-allyl-2,5-diphenylpent-4-enoic acid (**9h**) according to the general procedure; yield: 341.5 mg (0.77 mmol, 77%); white solid.

$^1\text{H NMR}$ (CDCl_3): δ = 7.82 (d, J = 7.3 Hz, 2 H), 7.69 (br s, 1 H), 7.37–7.30 (m, 3 H), 7.28–7.23 (m, 4 H), 7.19 (t, J = 7.3 Hz, 1 H), 7.13 (d, J = 7.3 Hz, 2 H), 7.11 (d, J = 7.3 Hz, 2 H), 6.29 (d, J = 14.4 Hz, 1 H), 5.64 (dt, J = 14.4, 7.5 Hz, 1 H), 5.42–5.35 (m, 1 H), 5.01 (d, J = 10.2 Hz, 1 H), 5.00 (d, J = 17.0 Hz, 1 H), 2.77 (d, J = 7.5 Hz, 2 H), 2.68 (dd, J = 14.8, 8.0 Hz, 1 H), 2.64 (dd, J = 14.8, 8.0 Hz, 1 H), 2.42 (s, 3 H).

$^{13}\text{C NMR}$ (CDCl_3): δ = 172.5, 145.0, 139.7, 136.9, 135.3, 134.4, 132.0, 129.4, 129.2, 128.5, 128.4, 128.1, 127.4, 127.0, 126.2, 123.4, 119.7, 55.0, 39.1, 38.3, 21.7.

HRMS (APCI): m/z [$M + H$] $^+$ calcd for $\text{C}_{27}\text{H}_{28}\text{NO}_3\text{S}$: 446.1784; found: 446.1792.

Alkenoic Acids 9a–h; General Procedure¹⁸

To a solution of *i*-Pr₂NH (2.5 equiv) in THF (4.0 M) at 0 °C was slowly added *n*-BuLi (1.63 M in hexane, 2.5 equiv), and the mixture was stirred at 0 °C for 1 h. To the solution was added the appropriate α,α -disubstituted acetic acid (1.0 equiv) in THF (0.8 M), and the mixture was stirred at 45 °C for 1.5 h. Allyl bromide (2.0 equiv) was added to the solution and the mixture was stirred at 45 °C overnight. H₂O was added to the mixture and the aqueous layer was washed with Et₂O. The aqueous layer was acidified with aq HCl, and the mixture was extracted with Et₂O (3 \times). The combined organic layers were washed with brine, dried (Na₂SO₄), filtered, and concentrated on a rotary evaporator. The solid residue was recrystallized from CHCl₃ and hexane to give **9**.

(*E*)-2-Allyl-2,5-diphenylpent-4-enoic Acid (9h)

This compound was prepared from (*E*)-2,5-diphenylpent-4-enoic acid (CAS: 351207-71-1) according to the general procedure; yield: 649.0 mg (2.2 mmol, 55%); white solid.

$^1\text{H NMR}$ (CDCl_3): δ = 7.39–7.34 (m, 4 H), 7.31–7.24 (m, 5 H), 7.22–7.18 (m, 1 H), 6.23 (d, J = 14.3 Hz, 1 H), 5.91 (dt, J = 14.3, 7.3 Hz, 1 H), 5.62 (ddt, J = 17.5, 10.1, 7.3 Hz, 1 H), 5.13 (d, J = 17.5 Hz, 1 H), 5.10 (d, J = 10.1 Hz, 1 H), 2.98 (dd, J = 13.9, 7.3 Hz, 1 H), 2.92 (dd, J = 13.9, 7.3 Hz, 1 H), 2.88 (dd, J = 13.9, 7.3 Hz, 1 H), 2.82 (dd, J = 13.9, 7.3 Hz, 1 H).

$^{13}\text{C NMR}$ (CDCl_3): δ = 180.1, 140.9, 137.3, 133.9, 133.1, 128.54, 128.46, 127.2, 126.5, 126.1, 124.7, 119.0, 53.7, 38.8, 38.0.

HRMS (APCI): m/z [$M + H$] $^+$ calcd for $\text{C}_{20}\text{H}_{21}\text{O}_2$: 293.1536; found: 293.1546.

Ir-Catalyzed Oxidative Cyclization (Tables 1, 2, and 4)

Additive (50 mol%), dppf (5 mol%), and [IrCl(coe)₂]₂ (5 mol% of Ir) were placed in a Schlenk tube under N₂. Toluene (0.25 M) and hydro-gene acceptor (3.0 equiv) were added and the mixture was stirred at r.t. for 10 min. *N*-Sulfonyl alkenyl amide **1** or alkenoic acid **9** (1.0 equiv) was added to the Schlenk tube and the tube was capped with a glass stopper and heated at 100 °C for 3 h with stirring. The mixture was passed through a short plug of silica gel with EtOAc as eluent and concentrated on a rotary evaporator. The residue was subjected to preparative TLC on silica gel to give the corresponding cyclization products.

Ir-Catalyzed Oxidative Cyclization of *N*-Sulfonyl Alkenyl Ureas Generated in Situ (Table 3)

To a solution of amine **5** (0.20 mmol) in CH₂Cl₂ (0.50 mL) was added *p*-toluenesulfonyl isocyanate (32.1 μL , 0.21 mmol), and the mixture was stirred at r.t. for 2 h. The solvent was removed under vacuum at r.t. To the mixture were added NaI (15.0 mg, 50 mol%), dppf (5.5 mg, 5 mol%), [IrCl(coe)₂]₂ (4.5 mg, 0.010 mmol of Ir), toluene (0.80 mL), and methyl vinyl ketone (50 μL , 0.60 mmol) under N₂. The Schlenk tube was capped with a glass stopper and heated at 100 °C for 3 h with stirring. The mixture was passed through a short plug of silica gel with EtOAc as an eluent and concentrated on a rotary evaporator. The residue was subjected to preparative TLC on silica gel to give the corresponding cyclization products.

5-Methylene-3,3-diphenyl-1-tosylpyrrolidin-2-one (2a) and 5-Methyl-3,3-diphenyl-1-tosylpyrrolidin-2-one (3a)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give a mixture of **2a** and **3a** (97/3) in 92% yield (37.1 mg, 0.092 mmol).

Compound 2a

Colorless oil.

$^1\text{H NMR}$ (CDCl_3): δ = 7.83 (d, J = 8.2 Hz, 2 H), 7.24 (d, J = 8.2 Hz, 2 H), 7.22–7.19 (m, 6 H), 7.11–7.08 (m, 4 H), 5.58–5.57 (m, 1 H), 4.67–4.66 (m, 1 H), 3.34–3.33 (m, 2 H), 2.43 (s, 3 H).

$^{13}\text{C NMR}$ (CDCl_3): δ = 174.0, 145.4, 140.7, 138.4, 134.8, 129.4, 128.4, 128.0, 127.5, 127.4, 94.6, 57.2, 42.5, 21.7.

HRMS (APCI): m/z [$M + H$] $^+$ calcd for $\text{C}_{24}\text{H}_{22}\text{NO}_3\text{S}$: 404.1315; found: 404.1309.

Compound 3a (CAS: 2019142-42-6)

Colorless oil.

$^1\text{H NMR}$ (CDCl_3): δ = 7.83 (d, J = 8.7 Hz, 2 H), 7.26–7.13 (m, 10 H), 7.07 (d, J = 8.7 Hz, 2 H), 4.29–4.23 (m, 1 H), 3.05 (dd, J = 13.3, 6.8 Hz, 1 H), 2.43 (s, 3 H), 2.41 (dd, J = 13.3, 7.5 Hz, 1 H), 1.52 (d, J = 6.1 Hz, 3 H).

3,3-Bis(4-methoxyphenyl)-5-methylene-1-tosylpyrrolidin-2-one (2b) and 3,3-Bis(4-methoxyphenyl)-5-methyl-1-tosylpyrrolidin-2-one (3b)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give a mixture of **2b** and **3b** (91/9) in 89% yield (82.8 mg, 0.178 mmol).

Compound 2b

Colorless oil.

¹H NMR (CDCl₃): δ = 7.80 (d, *J* = 8.1 Hz, 2 H), 7.22 (d, *J* = 8.1 Hz, 2 H), 7.00 (d, *J* = 8.1 Hz, 4 H), 6.72 (d, *J* = 8.1 Hz, 4 H), 5.56 (d, *J* = 1.4 Hz, 1 H), 4.64 (d, *J* = 1.4 Hz, 1 H), 3.76 (s, 6 H), 3.26 (s, 2 H), 2.42 (s, 3 H).

¹³C NMR (CDCl₃): δ = 174.4, 158.7, 145.3, 138.6, 134.8, 132.8, 129.4, 128.6, 127.9, 113.8, 94.4, 56.0, 55.2, 42.8, 21.7.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₆H₂₆NO₅S: 464.1526; found: 464.1544.

Compound 3b

Colorless oil.

¹H NMR (CDCl₃): δ = 7.81 (d, *J* = 8.1 Hz, 2 H), 7.22 (d, *J* = 8.1 Hz, 2 H), 7.05 (d, *J* = 8.9 Hz, 2 H), 6.97 (d, *J* = 8.9 Hz, 2 H), 6.76 (d, *J* = 8.9 Hz, 2 H), 6.70 (d, *J* = 8.9 Hz, 2 H), 4.25–4.19 (m, 1 H), 3.77 (s, 3 H), 3.75 (s, 3 H), 2.97 (dd, *J* = 13.3, 6.8 Hz, 1 H), 2.42 (s, 3 H), 2.32 (dd, *J* = 13.3, 7.5 Hz, 1 H), 1.52 (d, *J* = 6.1 Hz, 3 H).

¹³C NMR (CDCl₃): δ = 174.9, 158.7, 158.4, 144.7, 135.3, 134.4, 132.0, 129.2, 128.8, 128.4, 128.3, 113.8, 113.7, 56.7, 55.2, 53.6, 42.5, 22.0, 21.6.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₆H₂₈NO₅S: 466.1683; found: 466.1687.

3,3-Bis(4-chlorophenyl)-5-methylene-1-tosylpyrrolidin-2-one (2c) and 3,3-Bis(4-chlorophenyl)-5-methyl-1-tosylpyrrolidin-2-one (3c)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give a mixture of **2c** and **3c** (95/5) in 92% yield (87.0 mg, 0.184 mmol).

Compound 2c

Colorless oil.

¹H NMR (CDCl₃): δ = 7.77 (d, *J* = 8.5 Hz, 2 H), 7.23 (d, *J* = 8.5 Hz, 2 H), 7.17 (d, *J* = 8.8 Hz, 4 H), 7.01 (d, *J* = 8.8 Hz, 4 H), 5.61 (d, *J* = 1.4 Hz, 1 H), 4.69 (d, *J* = 1.4 Hz, 1 H), 3.26 (s, 2 H), 2.44 (s, 3 H).

¹³C NMR (CDCl₃): δ = 173.3, 145.7, 138.6, 137.8, 134.2, 133.8, 129.4, 128.8, 128.7, 127.9, 95.0, 56.3, 42.1, 21.7.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₄H₂₀³⁵Cl₂NO₃S: 472.0535; found: 472.0533.

Compound 3c

Colorless oil.

¹H NMR (CDCl₃): δ = 7.78 (d, *J* = 8.8 Hz, 2 H), 7.24–7.20 (m, 4 H), 7.14 (d, *J* = 8.8 Hz, 2 H), 7.06 (d, *J* = 8.8 Hz, 2 H), 6.98 (d, *J* = 8.8 Hz, 2 H), 4.26–4.20 (m, 1 H), 2.99 (dd, *J* = 13.4, 6.8 Hz, 1 H), 2.44 (s, 3 H), 2.31 (dd, *J* = 13.4, 7.8 Hz, 1 H), 1.54 (d, *J* = 5.4 Hz, 3 H).

¹³C NMR (CDCl₃): δ = 173.8, 145.2, 140.3, 137.7, 134.7, 133.7, 133.4, 129.3, 129.0, 128.8, 128.7, 128.2, 56.9, 53.6, 41.9, 22.2, 21.7.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₄H₂₂³⁵Cl₂NO₃S: 474.0692; found: 474.0707.

3,3-Dihexyl-5-methylene-1-tosylpyrrolidin-2-one (2d)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give **2d** in 81% yield (33.9 mg, 0.081 mmol) as a colorless oil.

¹H NMR (CDCl₃): δ = 7.93 (d, *J* = 8.6 Hz, 2 H), 7.31 (d, *J* = 8.6 Hz, 2 H), 5.50 (d, *J* = 2.1 Hz, 1 H), 4.53 (d, *J* = 1.4 Hz, 1 H), 2.52 (s, 2 H), 2.42 (s, 3 H), 1.45–1.33 (m, 4 H), 1.22–1.16 (m, 4 H), 1.15–1.05 (m, 10 H), 0.84 (t, *J* = 7.5 Hz, 6 H), 0.86–0.78 (m, 2 H).

¹³C NMR (CDCl₃): δ = 178.2, 145.2, 139.8, 135.4, 129.4, 128.0, 93.4, 47.3, 37.2, 37.1, 31.5, 29.5, 23.7, 22.4, 21.7, 14.0.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₄H₃₈NO₃S: 420.2567; found: 420.2563.

3,3-Dibenzyl-5-methylene-1-tosylpyrrolidin-2-one (2e) and 3,3-Dibenzyl-5-methyl-1-tosylpyrrolidin-2-one (3e)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give a mixture of **2e** and **3e** (97/3) in 89% yield (77.2 mg, 0.178 mmol) as colorless oils.

Compound 2e

¹H NMR (CDCl₃): δ = 7.82 (d, *J* = 8.1 Hz, 2 H), 7.32 (d, *J* = 8.1 Hz, 2 H), 7.18 (t, *J* = 7.5 Hz, 2 H), 7.11 (t, *J* = 7.5 Hz, 4 H), 6.94 (d, *J* = 7.5 Hz, 4 H), 5.10 (s, 1 H), 4.22 (s, 1 H), 3.08 (d, *J* = 13.3 Hz, 2 H), 2.63 (d, *J* = 13.3 Hz, 2 H), 2.50 (s, 2 H), 2.49 (s, 3 H).

¹³C NMR (CDCl₃): δ = 177.0, 145.1, 138.7, 135.7, 135.3, 130.2, 129.4, 128.33, 128.27, 126.8, 94.0, 50.4, 42.6, 34.2, 21.7.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₆H₂₆NO₃S: 432.1628; found: 432.1635.

Compound 3e

¹H NMR (CDCl₃): δ = 7.87 (d, *J* = 8.1 Hz, 2 H), 7.34 (d, *J* = 8.1 Hz, 2 H), 7.24–7.18 (m, 3 H), 7.14 (d, *J* = 8.1 Hz, 1 H), 7.07 (t, *J* = 8.1 Hz, 2 H), 7.03 (d, *J* = 8.1 Hz, 2 H), 6.94 (d, *J* = 8.1 Hz, 2 H), 3.56–3.49 (m, 1 H), 3.20 (d, *J* = 13.6 Hz, 1 H), 3.12 (d, *J* = 13.6 Hz, 1 H), 2.57 (d, *J* = 10.2 Hz, 1 H), 2.55 (d, *J* = 10.2 Hz, 1 H), 2.50 (s, 3 H), 2.22 (dd, *J* = 13.6, 9.5 Hz, 1 H), 1.54 (dd, *J* = 13.6, 5.4 Hz, 1 H), 0.78 (d, *J* = 6.1 Hz, 3 H).

¹³C NMR (CDCl₃): δ = 177.5, 144.6, 136.8, 136.3, 136.0, 130.4, 130.2, 129.2, 128.6, 128.4, 128.3, 126.9, 126.8, 53.0, 51.5, 44.8, 44.0, 33.0, 22.2, 21.7.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₆H₂₈NO₃S: 434.1784; found: 434.1795.

3-Methylene-2-tosyl-2-azaspiro[4.5]decan-1-one (2f), 3-Methyl-2-tosyl-2-azaspiro[4.5]dec-3-en-1-one (2f'), and 3-Methyl-2-tosyl-2-azaspiro[4.5]decan-1-one (3f)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give a mixture of **2f**, **2f'**, **3f** (23/76/1) in 72% yield (51.7 mg, 0.162 mmol). Compound **2f** could not be separated from compound **2f'**.

Compound 2f

Colorless oil.

¹H NMR (CDCl₃): δ = 7.89 (d, *J* = 8.1 Hz, 2 H), 7.30 (d, *J* = 8.1 Hz, 2 H), 5.48 (d, *J* = 1.4 Hz, 1 H), 4.56 (d, *J* = 1.4 Hz, 1 H), 2.52 (s, 2 H), 2.41 (s, 3 H), 1.70–1.20 (m, 10 H).

¹³C NMR (CDCl₃): δ = 178.3, 145.2, 139.2, 135.4, 129.5, 127.8, 94.4, 44.9, 38.2, 32.0, 25.0, 21.6.

Compound 2f'

Colorless oil.

¹H NMR (CDCl₃): δ = 7.87 (d, *J* = 8.1 Hz, 2 H), 7.31 (d, *J* = 8.1 Hz, 2 H), 5.38 (s, 1 H), 2.42 (s, 3 H), 2.29 (s, 3 H), 1.72–1.52 (m, 4 H), 1.36–1.22 (m, 6 H).¹³C NMR (CDCl₃): δ = 180.6, 144.8, 137.4, 136.2, 129.6, 127.7, 113.5, 50.0, 32.9, 25.2, 22.0, 21.6, 16.8.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₇H₂₂NO₃S: 320.1315; found: 320.1305.**Compound 3f**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.91 (d, *J* = 7.8 Hz, 2 H), 7.30 (d, *J* = 7.8 Hz, 2 H), 4.32–4.26 (m, 1 H), 2.42 (s, 3 H), 2.23 (dd, *J* = 12.9, 8.2 Hz, 1 H), 1.54 (d, *J* = 6.1 Hz, 3 H), 1.70–1.52 (m, 5 H), 1.43–1.37 (m, 2 H), 1.29–1.20 (m, 4 H).¹³C NMR (CDCl₃): δ = 178.6, 144.7, 136.1, 129.4, 128.2, 53.3, 45.5, 38.2, 33.6, 33.0, 25.1, 23.4, 21.7, 21.63, 21.57.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₇H₂₄NO₃S: 322.1471; found: 322.1478.**3,3-Dimethyl-5-methylene-1-tosylpyrrolidin-2-one (2g), 3,3,5-Trimethyl-1-tosyl-1,3-dihydro-2H-pyrrol-2-one (2g'), and 3,3,5-Trimethyl-1-tosylpyrrolidin-2-one (3g)**The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give a mixture of **2g**, **2g'**, and **3g** (23/74/3) in 81% yield (40.0 mg, 0.144 mmol).**Compound 2g (CAS: 1875033-08-1)**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.92 (d, *J* = 8.1 Hz, 2 H), 7.33 (d, *J* = 8.1 Hz, 2 H), 5.52 (d, *J* = 2.0 Hz, 1 H), 4.58 (d, *J* = 2.0 Hz, 1 H), 2.47 (s, 2 H), 2.44 (s, 3 H), 1.09 (s, 6 H).**Compound 2g'**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.87 (d, *J* = 7.2 Hz, 2 H), 7.32 (d, *J* = 7.2 Hz, 2 H), 5.07 (s, 1 H), 2.43 (s, 3 H), 2.26 (s, 3 H), 1.07 (s, 6 H).¹³C NMR (CDCl₃): δ = 181.2, 144.9, 137.0, 136.0, 129.6, 127.7, 116.3, 45.2, 23.7, 21.6, 16.6.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₄H₁₈NO₃S: 280.1002; found: 280.1005.**Compound 3g**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.92 (d, *J* = 8.1 Hz, 2 H), 7.31 (d, *J* = 8.1 Hz, 2 H), 4.33–4.27 (m, 1 H), 2.43 (s, 3 H), 2.13 (dd, *J* = 12.9, 8.2 Hz, 1 H), 1.55 (dd, *J* = 12.9, 6.8 Hz, 1 H), 1.55 (d, *J* = 6.1 Hz, 3 H), 1.14 (s, 3 H), 1.01 (s, 3 H).¹³C NMR (CDCl₃): δ = 179.0, 144.8, 136.0, 129.4, 128.2, 53.1, 42.2, 41.2, 25.2, 23.0, 21.7.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₄H₂₀NO₃S: 282.1158; found: 282.1172.**5-Methyl-1-tosyl-1,5-dihydro-2H-pyrrol-2-one (2h') and 5-Methyl-1-tosylpyrrolidin-2-one (3h)**The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give a mixture of **2h'** and **3h** (92/8) in 27% yield (13.6 mg, 0.054 mmol) as colorless oils.**Compound 2h' (CAS: 96013-62-6)**¹H NMR (CDCl₃): δ = 7.96 (d, *J* = 8.1 Hz, 2 H), 7.32 (d, *J* = 8.1 Hz, 2 H), 7.14 (dd, *J* = 6.0, 1.7 Hz, 1 H), 5.97 (dd, *J* = 6.0, 1.7 Hz, 1 H), 4.87 (qt, *J* = 6.3, 1.7 Hz, 1 H), 2.42 (s, 3 H), 1.58 (d, *J* = 6.3 Hz, 3 H).**Compound 3h (CAS: 118429-46-2)**¹H NMR (CDCl₃): δ = 7.95 (d, *J* = 8.2 Hz, 2 H), 7.32 (d, *J* = 8.2 Hz, 2 H), 4.55–4.50 (m, 1 H), 2.59–2.52 (m, 1 H), 2.43 (s, 3 H), 2.39–2.32 (m, 1 H), 2.31–2.23 (m, 1 H), 1.74–1.69 (m, 1 H), 1.47 (d, *J* = 6.1 Hz, 3 H).**3-Cinnamyl-5-methylene-3-phenyl-1-tosylpyrrolidin-2-one (2i) and 3-Cinnamyl-5-methyl-3-phenyl-1-tosylpyrrolidin-2-one (3i)**The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give a mixture of **2i** and **3i** (98/2) in 83% yield (73.3 mg, 0.166 mmol).**Compound 2i**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.86 (d, *J* = 7.5 Hz, 2 H), 7.33–7.24 (m, 7 H), 7.23–7.18 (m, 3 H), 7.13 (d, *J* = 7.5 Hz, 2 H), 6.31 (d, *J* = 14.4 Hz, 1 H), 5.75 (dt, *J* = 14.4, 7.4 Hz, 1 H), 5.52 (d, *J* = 1.3 Hz, 1 H), 4.62 (d, *J* = 1.3 Hz, 1 H), 3.07 (d, *J* = 14.0 Hz, 1 H), 2.99 (d, *J* = 14.0 Hz, 1 H), 2.77 (dd, *J* = 13.8, 7.4 Hz, 1 H), 2.71 (dd, *J* = 13.8, 7.4 Hz, 1 H), 2.39 (s, 3 H).¹³C NMR (CDCl₃): δ = 175.3, 145.3, 139.3, 138.8, 136.7, 135.1, 134.6, 129.4, 128.7, 128.4, 127.9, 127.53, 127.50, 126.2, 126.1, 123.6, 94.7, 52.1, 42.0, 38.4, 21.7.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₇H₂₆NO₃S: 444.1628; found: 444.1625.**Compound 3i**

Colorless oil; d.r. = 60:40.

¹H NMR (CDCl₃): δ = 7.94 [d, *J* = 8.2 Hz, 2 H (minor)], 7.75 [d, *J* = 8.2 Hz, 2 H (major)], 7.35–7.15 [m, 10 H (major) + 12 H (minor)], 7.10 [d, *J* = 8.2 Hz, 2 H (major)], 6.33 [d, *J* = 14.0 Hz, 1 H (major)], 6.30 [d, *J* = 14.0 Hz, 1 H (minor)], 5.87 [dt, *J* = 14.0, 7.6 Hz, 1 H (major)], 5.74 [dt, *J* = 14.0, 7.6 Hz, 1 H (minor)], 4.42–4.36 [m, 1 H (minor)], 4.11–4.05 [m, 1 H (major)], 2.74–2.62 [m, 3 H (major) + 2 H (minor)], 2.54 [dd, *J* = 14.0, 8.2 Hz, 1 H (minor)], 2.43 [s, 3 H (minor)], 2.42 [s, 3 H (major)], 2.24 [dd, *J* = 14.0, 2.7 Hz, 1 H (minor)], 1.90 [dd, *J* = 13.3, 9.2 Hz, 1 H (major)], 1.59 [d, *J* = 6.1 Hz, 3 H (major)], 1.25 [d, *J* = 6.1 Hz, 3 H (minor)].HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₇H₂₈NO₃S: 446.1784; found: 446.1771.**1-Methanesulfonyl-5-methylene-3,3-diphenylpyrrolidin-2-one (2j) and 1-Methanesulfonyl-5-methyl-3,3-diphenylpyrrolidin-2-one (3j)**The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give a mixture of **2j** and **3j** (97/3) in 95% yield (62.2 mg, 0.190 mmol).

Compound 2j

Colorless oil.

¹H NMR (CDCl₃): δ = 7.36–7.28 (m, 10 H), 5.41 (d, *J* = 1.7 Hz, 1 H), 4.68 (d, *J* = 1.7 Hz, 1 H), 3.44 (s, 2 H), 3.29 (s, 3 H).¹³C NMR (CDCl₃): δ = 175.3, 140.9, 138.0, 128.7, 127.7, 127.5, 95.1, 57.3, 42.8, 41.3.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₈H₁₈NO₃S: 328.1002; found: 328.1010.**Compound 3j (CAS: 1993426-09-7)**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.36–7.31 (m, 8 H), 7.31–7.25 (m, 2 H), 4.31–4.25 (m, 1 H), 3.26 (s, 3 H), 3.13 (dd, *J* = 13.3, 6.8 Hz, 1 H), 2.56 (dd, *J* = 13.3, 6.1 Hz, 1 H), 1.43 (d, *J* = 6.1 Hz, 3 H).**1-Benzyl-4-methylene-3-tosylimidazolidin-2-one (7a), 1-Benzyl-4-methyl-3-tosyl-1,3-dihydro-2H-imidazol-2-one (7a'), and 1-Benzyl-4-methyl-3-tosylimidazolidin-2-one (8a)**The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give a mixture of **7a**, **7a'**, and **8a** (10/86/4) in 66% yield (45.2 mg, 0.132 mmol).**Compound 7a**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.96 (d, *J* = 8.1 Hz, 2 H), 7.34 (d, *J* = 8.1 Hz, 2 H), 7.32–7.27 (m, 3 H), 7.15–7.12 (m, 2 H), 5.51 (q, *J* = 2.3 Hz, 1 H), 4.43 (q, *J* = 2.3 Hz, 1 H), 4.36 (s, 2 H), 3.81 (t, *J* = 2.3 Hz, 2 H), 2.45 (s, 3 H).¹³C NMR (CDCl₃): δ = 153.0, 145.1, 135.6, 134.9, 134.4, 129.6, 128.9, 128.2, 128.1, 127.9, 91.9, 47.3, 47.2, 21.7.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₈H₁₉N₂O₃S: 343.1111; found: 343.1121.**Compound 7a'**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.99 (d, *J* = 8.1 Hz, 2 H), 7.34 (d, *J* = 8.1 Hz, 2 H), 7.32–7.27 (m, 3 H), 7.14 (d, *J* = 8.1 Hz, 2 H), 5.80 (s, 1 H), 4.58 (s, 2 H), 2.44 (s, 3 H), 2.26 (s, 3 H).¹³C NMR (CDCl₃): δ = 150.9, 145.3, 135.6, 135.5, 129.7, 128.8, 128.13, 128.08, 128.0, 119.0, 110.1, 46.8, 21.7, 13.3.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₈H₁₉N₂O₃S: 343.1111; found: 343.1112.**Compound 8a**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.96 (d, *J* = 8.1 Hz, 2 H), 7.33 (d, *J* = 8.1 Hz, 2 H), 7.31–7.26 (m, 3 H), 7.13 (d, *J* = 8.1 Hz, 2 H), 4.34 (dd, *J* = 14.7 Hz, 1 H), 4.37–4.31 (m, 1 H), 4.27 (d, *J* = 14.7 Hz, 1 H), 3.40 (t, *J* = 9.1 Hz, 1 H), 2.79 (dd, *J* = 9.1, 4.1 Hz, 1 H), 2.44 (s, 3 H), 1.44 (d, *J* = 6.1 Hz, 3 H).¹³C NMR (CDCl₃): δ = 153.8, 144.4, 136.4, 135.4, 129.4, 128.7, 128.2, 128.1, 127.9, 50.4, 49.1, 47.6, 21.9, 21.6.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₈H₂₁N₂O₃S: 345.1267; found: 345.1284.**1-Benzyl-5-methyl-4-methylene-3-tosylimidazolidin-2-one (7b) and 1-Benzyl-trans-4,5-dimethyl-3-tosylimidazolidin-2-one (8b)**The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/2) to give a mixture of **7b** and **8b** (12/88) in 78% yield (55.5 mg, 0.156 mmol).**Compound 7b**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.95 (d, *J* = 8.2 Hz, 2 H), 7.34 (d, *J* = 8.2 Hz, 2 H), 7.30–7.25 (m, 3 H), 7.12–7.08 (m, 2 H), 5.55 (t, *J* = 2.2 Hz, 1 H), 4.80 (d, *J* = 15.3 Hz, 1 H), 4.42 (t, *J* = 2.2 Hz, 1 H), 3.97 (d, *J* = 15.3 Hz, 1 H), 3.94–3.90 (m, 1 H), 2.46 (s, 3 H), 1.21 (d, *J* = 6.1 Hz, 3 H).¹³C NMR (CDCl₃): δ = 152.6, 145.0, 141.1, 135.7, 135.3, 129.6, 128.8, 128.0, 127.94, 127.90, 91.8, 52.9, 44.7, 21.7, 19.7.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₉H₂₁N₂O₃S: 357.1267; found: 357.1268.**Compound 8b**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.95 (d, *J* = 7.9 Hz, 2 H), 7.33 (d, *J* = 7.9 Hz, 2 H), 7.31–7.25 (m, 3 H), 7.16 (d, *J* = 7.9 Hz, 2 H), 4.72 (d, *J* = 15.0 Hz, 1 H), 3.92 (d, *J* = 15.0 Hz, 1 H), 3.83 (qd, *J* = 6.1, 3.8 Hz, 1 H), 2.99 (qd, *J* = 6.1, 3.8 Hz, 1 H), 2.44 (s, 3 H), 1.39 (d, *J* = 6.1 Hz, 3 H), 1.07 (d, *J* = 6.1 Hz, 3 H).¹³C NMR (CDCl₃): δ = 153.3, 144.4, 136.3, 135.8, 129.5, 128.7, 128.1, 128.0, 127.8, 58.2, 55.7, 44.9, 21.6, 21.0, 18.1.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₉H₂₃N₂O₃S: 359.1424; found: 359.1423.**1-Benzyl-trans-5-cyclohexyl-4-methyl-3-tosylimidazolidin-2-one (8c)**The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/3) to give a mixture of **8c** in 86% yield (73.4 mg, 0.172 mmol) as a colorless oil.¹H NMR (CDCl₃): δ = 7.96 (d, *J* = 8.2 Hz, 2 H), 7.34–7.26 (m, 5 H), 7.19 (d, *J* = 8.2 Hz, 2 H), 4.82 (d, *J* = 14.9 Hz, 1 H), 4.09 (qd, *J* = 6.4, 2.9 Hz, 1 H), 3.86 (d, *J* = 14.9 Hz, 1 H), 2.79 (t, *J* = 2.9 Hz, 1 H), 2.43 (s, 3 H), 1.74 (br d, *J* = 12.9 Hz, 1 H), 1.68–1.58 (m, 2 H), 1.53–1.47 (m, 1 H), 1.33 (br d, *J* = 13.3 Hz, 1 H), 1.30 (d, *J* = 6.4 Hz, 3 H), 1.24 (br d, *J* = 13.3 Hz, 1 H), 1.21–1.12 (m, 1 H), 1.11–1.03 (m, 1 H), 1.03–0.93 (m, 2 H), 0.72–0.64 (m, 1 H).¹³C NMR (CDCl₃): δ = 153.3, 144.4, 136.7, 135.9, 129.4, 128.7, 128.09, 128.07, 127.8, 64.0, 51.7, 45.2, 38.3, 28.0, 26.2, 26.1, 25.6, 24.9, 23.2, 21.6.HRMS (APCI): *m/z* [M + H]⁺ calcd for C₂₄H₃₁N₂O₃S: 427.2050; found: 427.2039.**5-Methylene-3,3-diphenyldihydrofuran-2(3H)-one (10a) and 5-Methyl-3,3-diphenyldihydrofuran-2(3H)-one (11a)**The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/4) to give a mixture of **10a** and **11a** (97/3) in 95% yield (43.9 mg, 0.190 mmol).**Compound 10a (CAS: 137415-99-7)**

Colorless oil.

¹H NMR (CDCl₃): δ = 7.36–7.33 (m, 8 H), 7.32–7.28 (m, 2 H), 4.82–4.80 (m, 1 H), 4.44–4.42 (m, 1 H), 3.57 (t, *J* = 1.7 Hz, 2 H).

Compound 11a (CAS: 1729-20-0)

Colorless oil.

¹H NMR (CDCl₃): δ = 7.38–7.21 (m, 10 H), 4.51–4.45 (m, 1 H), 3.06 (dd, *J* = 12.9, 4.8 Hz, 1 H), 2.59 (dd, *J* = 12.9, 10.2 Hz, 1 H), 1.46 (d, *J* = 6.1 Hz, 3 H).

3,3-Bis(4-methylphenyl)-5-methylenedihydrofuran-2(3H)-one (10b) and 3,3-Bis(4-methylphenyl)-5-methyldihydrofuran-2(3H)-one (11b)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/4) to give a mixture of **10b** and **11b** (98/2) in 95% yield (52.9 mg, 0.190 mmol).

Compound 10b

Colorless oil.

¹H NMR (CDCl₃): δ = 7.21 (d, *J* = 8.1 Hz, 4 H), 7.14 (d, *J* = 8.1 Hz, 4 H), 4.79–4.77 (m, 1 H), 4.41–4.40 (m, 1 H), 3.53 (s, 2 H), 2.33 (s, 6 H).

¹³C NMR (CDCl₃): δ = 175.4, 152.9, 138.0, 137.4, 129.4, 127.2, 89.2, 56.6, 41.8, 21.0.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₉H₁₉O₂: 279.1380; found: 279.1392.

Compound 11b [CAS: 1803403-16-8 for (R)-11b]

Colorless oil.

¹H NMR (CDCl₃): δ = 7.25 (d, *J* = 8.1 Hz, 2 H), 7.19 (d, *J* = 8.1 Hz, 2 H), 7.16 (d, *J* = 8.1 Hz, 2 H), 7.11 (d, *J* = 8.1 Hz, 2 H), 4.50–4.44 (m, 1 H), 3.02 (dd, *J* = 12.9, 4.8 Hz, 1 H), 2.55 (dd, *J* = 12.9, 10.2 Hz, 1 H), 2.34 (s, 3 H), 2.31 (s, 3 H), 1.46 (d, *J* = 6.1 Hz, 3 H).

3,3-Bis(4-methoxyphenyl)-5-methylenedihydrofuran-2(3H)-one (10c) and 3,3-Bis(4-methoxyphenyl)-5-methyldihydrofuran-2(3H)-one (11c)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/3) to give a mixture of **10c** and **11c** (99/1) in 93% yield (58.0 mg, 0.186 mmol).

Compound 10c

Colorless oil.

¹H NMR (CDCl₃): δ = 7.24 (d, *J* = 8.9 Hz, 4 H), 6.86 (d, *J* = 8.9 Hz, 4 H), 4.79–4.78 (m, 1 H), 4.42–4.41 (m, 1 H), 3.79 (s, 6 H), 3.50 (s, 2 H).

¹³C NMR (CDCl₃): δ = 175.7, 158.9, 152.9, 133.1, 128.4, 114.0, 89.2, 56.0, 55.3, 42.0.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₉H₁₉O₄: 311.1278; found: 311.1287.

Compound 11c [CAS: 1803403-17-9 for (R)-11c]

Colorless oil.

¹H NMR (CDCl₃): δ = 7.26 (d, *J* = 8.9 Hz, 2 H), 7.19 (d, *J* = 8.9 Hz, 2 H), 6.86 (d, *J* = 8.9 Hz, 2 H), 6.82 (d, *J* = 8.9 Hz, 2 H), 4.48–4.42 (m, 1 H), 3.78 (s, 3 H), 3.76 (s, 3 H), 2.99 (dd, *J* = 12.9, 4.8 Hz, 1 H), 2.51 (dd, *J* = 12.9, 10.2 Hz, 1 H), 1.44 (d, *J* = 6.1 Hz, 3 H).

3,3-Bis(4-fluorophenyl)-5-methylenedihydrofuran-2(3H)-one (10d) and 3,3-Bis(4-fluorophenyl)-5-methyldihydrofuran-2(3H)-one (11d)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/4) to give a mixture of **10d** and **11d** (98/2) in 90% yield (26.1 mg, 0.090 mmol).

Compound 10d

Colorless oil.

¹H NMR (CDCl₃): δ = 7.29 (dd, *J* = 8.9, 4.8 Hz, 4 H), 7.04 (t, *J* = 8.9 Hz, 4 H), 4.84–4.82 (m, 1 H), 4.47–4.46 (m, 1 H), 3.52 (s, 2 H).

¹³C NMR (CDCl₃): δ = 174.9, 162.2 (d, *J*_{FC} = 248 Hz), 152.2, 136.4 (d, *J*_{FC} = 3 Hz), 129.1 (d, *J*_{FC} = 9 Hz), 115.7 (d, *J*_{FC} = 22 Hz), 89.9, 56.1, 41.8.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₇H₁₃F₂O₂: 287.0878; found: 287.0891.

Compound 11d [CAS: 1803403-18-0 for (R)-11d]

Colorless oil.

¹H NMR (CDCl₃): δ = 7.33–7.29 (m, 2 H), 7.28–7.24 (m, 2 H), 7.04 (t, *J* = 8.7 Hz, 2 H), 6.99 (t, *J* = 8.7 Hz, 2 H), 4.49–4.43 (m, 1 H), 3.01 (dd, *J* = 12.9, 4.8 Hz, 1 H), 2.53 (dd, *J* = 12.9, 10.2 Hz, 1 H), 1.46 (d, *J* = 6.1 Hz, 3 H).

3,3-Bis(4-chlorophenyl)-5-methylenedihydrofuran-2(3H)-one (10e) and 3,3-Bis(4-chlorophenyl)-5-methyldihydrofuran-2(3H)-one (11e)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/4) to give a mixture of **10e** and **11e** (98/2) in 90% yield (57.7 mg, 0.180 mmol).

Compound 10e

Colorless oil.

¹H NMR (CDCl₃): δ = 7.33 (d, *J* = 8.1 Hz, 4 H), 7.25 (d, *J* = 8.1 Hz, 4 H), 4.84 (q, *J* = 1.7 Hz, 1 H), 4.47 (q, *J* = 1.7 Hz, 1 H), 3.51 (t, *J* = 1.7 Hz, 2 H).

¹³C NMR (CDCl₃): δ = 174.4, 152.0, 138.9, 134.1, 129.0, 128.7, 90.1, 56.3, 41.4.

HRMS (APCI): *m/z* [M + H]⁺ calcd for C₁₇H₁₃³⁵Cl₂O₂: 319.0287; found: 319.0286.

Compound 11e [CAS: 1803403-19-1 for (R)-11e]

White solid.

¹H NMR (CDCl₃): δ = 7.32 (d, *J* = 8.8 Hz, 2 H), 7.29–7.22 (m, 6 H), 4.49–4.43 (m, 1 H), 2.99 (dd, *J* = 12.9, 4.8 Hz, 1 H), 2.53 (dd, *J* = 12.9, 10.9 Hz, 1 H), 1.46 (d, *J* = 6.1 Hz, 3 H).

3,3-Dibenzyl-5-methylenedihydrofuran-2(3H)-one (10f) and 3,3-Dibenzyl-5-methyldihydrofuran-2(3H)-one (11f)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc/hexane (1/4) to give a mixture of **10f** and **11f** (99/1) in 83% yield (46.8 mg, 0.166 mmol).

Compound 10f

Colorless oil.

¹H NMR (CDCl₃): δ = 7.31–7.24 (m, 6 H), 7.17 (d, *J* = 8.1 Hz, 4 H), 4.34 (q, *J* = 1.7 Hz, 1 H), 3.94–3.92 (m, 1 H), 3.21 (d, *J* = 13.5 Hz, 2 H), 2.81 (d, *J* = 13.5 Hz, 2 H), 2.71 (t, *J* = 1.7 Hz, 2 H).

^{13}C NMR (CDCl_3): δ = 178.5, 153.1, 135.7, 130.3, 128.5, 127.2, 88.3, 51.1, 42.9, 32.9.

HRMS (APCI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{19}\text{H}_{19}\text{O}_2$: 279.1380; found: 279.1390.

Compound 11f [CAS: 1803403-20-4 for (R)-11f]

Colorless oil.

^1H NMR (CDCl_3): δ = 7.31–7.17 (m, 10 H), 3.41–3.35 (m, 1 H), 3.27 (d, J = 13.5 Hz, 1 H), 3.16 (d, J = 13.5 Hz, 1 H), 2.77 (d, J = 13.2 Hz, 1 H), 2.71 (d, J = 13.2 Hz, 1 H), 2.17 (dd, J = 13.2, 7.1 Hz, 1 H), 1.77 (dd, J = 13.2, 9.2 Hz, 1 H), 0.84 (d, J = 6.8 Hz, 3 H).

3,3-Dimethyl-5-methylenedihydrofuran-2(3H)-one (10g) (CAS: 86972-24-9)

The crude mixture was subjected to column chromatography on silica gel with Et_2O /pentane (1:4) to give a mixture of **10g** in 59% yield (22.5 mg, 0.177 mmol) as a colorless oil.

^1H NMR (CDCl_3): δ = 4.75 (d, J = 1.9 Hz, 1 H), 4.32 (d, J = 1.9 Hz, 1 H), 2.69 (t, J = 1.9 Hz, 2 H), 1.30 (s, 6 H).

3-Cinnamyl-5-methylene-3-phenyldihydrofuran-2(3H)-one (10h) and 3-Cinnamyl-5-methyl-3-phenyldihydrofuran-2(3H)-one (11h)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc /hexane (1/4) to give a mixture of **10h** and **11h** (99/1) in 91% yield (53.1 mg, 0.182 mmol).

Compound 10h

Colorless oil.

^1H NMR (CDCl_3): δ = 7.50 (d, J = 7.8 Hz, 2 H), 7.40 (t, J = 7.8 Hz, 2 H), 7.32 (t, J = 7.8 Hz, 1 H), 7.30–7.27 (m, 4 H), 7.25–7.21 (m, 1 H), 6.48 (d, J = 14.4 Hz, 1 H), 6.00 (dt, J = 14.4, 7.5 Hz, 1 H), 4.76 (d, J = 1.9 Hz, 1 H), 4.36 (J = 1.9 Hz, 1 H), 3.25 (dt, J = 16.0, 1.9 Hz, 1 H), 3.21 (dt, J = 16.0, 1.9 Hz, 1 H), 2.91 (dd, J = 13.5, 7.5 Hz, 1 H), 2.88 (dd, J = 13.5, 7.5 Hz, 1 H).

^{13}C NMR (CDCl_3): δ = 176.4, 153.1, 139.2, 136.7, 135.1, 128.9, 128.5, 127.7, 127.6, 126.3, 126.1, 123.4, 89.2, 52.3, 42.7, 37.4.

HRMS (APCI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{O}_2$: 291.1380; found: 291.1381.

Compound 11h

Colorless oil; d.r. = 70:30.

^1H NMR (CDCl_3): δ = 7.56 [d, J = 7.5 Hz, 2 H (minor)], 7.45 [d, J = 7.5 Hz, 2 H (major)], 7.40–7.20 [m, 8 H (major) + 8 H (minor)], 6.45 [d, J = 16.3 Hz, 1 H (major)], 6.42 [d, J = 16.3 Hz, 1 H (minor)], 6.07–5.97 [m, 1 H (major) + 1 H (minor)], 4.68–4.62 [m, 1 H (minor)], 4.41–4.35 [m, 1 H (major)], 2.86–2.72 [m, 3 H (major) + 3 H (minor)], 2.32 [dd, J = 13.2, 7.8 Hz, 1 H (minor)], 2.12 [t, J = 12.2 Hz, 1 H (major)], 1.40 [d, J = 6.1 Hz, 3 H (major)], 1.34 [d, J = 6.1 Hz, 3 H (minor)].

HRMS (APCI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{20}\text{H}_{21}\text{O}_2$: 293.1542; found: 293.1550.

4-Methyl-5-methylene-3,3-diphenyldihydrofuran-2(3H)-one (10i) and 4,5-Dimethyl-3,3-diphenyldihydrofuran-2(3H)-one (11i)

The crude mixture was subjected to preparative TLC on silica gel with EtOAc /hexane (1/5) to give a mixture of **10i** and **11i** (90/10) in 84% yield (44.0 mg, 0.168 mmol).

Compound 10i

White solid.

^1H NMR (CDCl_3): δ = 7.50 (d, J = 8.2 Hz, 2 H), 7.41–7.32 (m, 3 H), 7.30–7.24 (m, 3 H), 6.99–6.94 (m, 2 H), 4.86 (t, J = 2.4 Hz, 1 H), 4.38 (t, J = 2.4 Hz, 1 H), 3.93 (qt, J = 6.8, 2.4 Hz, 1 H), 0.97 (d, J = 6.8 Hz, 3 H).

^{13}C NMR (CDCl_3): δ = 175.1, 158.6, 139.1, 138.8, 128.4, 128.2, 127.8, 127.4, 88.9, 60.4, 41.8, 14.0.

HRMS (ESI): m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{18}\text{H}_{16}\text{O}_2\text{Na}$: 287.1048; found: 287.1039.

Compound 11i

Colorless oil.

^1H NMR (CDCl_3): δ = 7.45–7.41 (m, 2 H), 7.39–7.34 (m, 2 H), 7.33–7.25 (m, 4 H), 6.97–6.93 (m, 2 H), 4.14–4.06 (m, 1 H), 3.04–2.95 (m, 1 H), 1.49 (d, J = 6.0 Hz, 3 H), 0.90 (d, J = 6.0 Hz, 3 H).

^{13}C NMR (CDCl_3): δ = 177.7, 140.2, 138.7, 129.1–127.2 (br), 78.4, 61.3, 45.4 (br), 18.0 (br), 11.9.

HRMS (ESI): m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{18}\text{H}_{18}\text{O}_2\text{Na}$: 289.1205; found: 289.1214.

Stoichiometric Reaction of 1h with $[\text{IrCl}(\text{coe})_2]_2/\text{dppf}$

Dppf (11.0 mg, 0.020 mmol) and $[\text{IrCl}(\text{coe})_2]_2$ (5.1 mg, 0.020 mmol Ir) were placed in a Schlenk tube under N_2 . C_6D_6 (0.60 mL) was added to the Schlenk tube and the mixture was stirred at r.t. for 15 min. Compound **1h** and 1,4-dimethoxybenzene (3.3 mg, 0.024 mmol as an internal standard) were added to the Schlenk tube and the mixture was stirred at r.t. for 30 min. The resulting solution was transferred to an NMR tube capped with a rubber septum by use of a syringe pump. The signal of the hydride was observed at δ = –29.5 (t, J_{PH} = 22 Hz), –27.7 (dd, J_{PH} = 27, 16 Hz), –27.4 (dd, J_{PH} = 29, 18 Hz), –23.7 (t, J_{PH} = 20 Hz), and –22.4 (t, J_{PH} = 22 Hz). The yield of the iridium hydride complex was estimated to be 3%, 23%, 9%, 10%, and 6%, respectively.

Funding Information

Japan Society for the Promotion of Science, Grant / Award Number: 'JP15H03810'.

Acknowledgment

This work was supported by JSPS KAKENHI Grant Number JP15H03810. M.N. thanks the JSPS for a Research Fellowship for Young Scientists.

Supporting Information

Supporting information for this article is available online at <https://doi.org/10.1055/s-0036-1588435>.

References

- (1) Present Address: Department of Chemistry, Graduate School of Science, Osaka City University, 3-3-138 Sugimoto Sumiyoshiku, Osaka 558-8585, Japan.
- (2) For recent reviews, see: (a) Baiju, T. V.; Gravel, E.; Doris, E.; Namboothiri, I. N. N. *Tetrahedron Lett.* **2016**, 57, 3993. (b) Obora, Y.; Ishii, Y. *Catalysts* **2013**, 3, 794. (c) McDonald, R. I.; Liu, G.;

- Stahl, S. S. *Chem. Rev.* **2011**, *111*, 2981. (d) Minatti, A.; Muñoz, K. *Chem. Soc. Rev.* **2007**, *36*, 1142. (e) Kotov, V.; Scarborough, C. C.; Stahl, S. S. *Inorg. Chem.* **2007**, *46*, 1910. (f) Beller, M.; Breindl, C.; Eichberger, M.; Hartung, C. G.; Seayad, J.; Thiel, O. R.; Tillack, A.; Trauthwein, H. *Synlett* **2002**, 1579. (g) Müller, T. E.; Beller, M. *Chem. Rev.* **1998**, *98*, 675.
- (3) For pioneering works on Wacker oxidation, see: (a) Smidt, J.; Hafner, W.; Jira, R.; Sieber, R.; Sedlmeier, J.; Sabel, A. *Angew. Chem., Int. Ed. Engl.* **1962**, *1*, 80. (b) Hegedus, L. S.; Allen, G. F.; Bozell, J. J.; Waterman, E. L. *J. Am. Chem. Soc.* **1978**, *100*, 5800. (c) Tsuji, J. *Synthesis* **1984**, 369.
- (4) (a) Brunet, J.-J.; Nelbecker, D.; Philippot, K. *Tetrahedron Lett.* **1993**, *34*, 3877. (b) Beller, M.; Trauthwein, H.; Eichberger, M.; Breindl, C.; Herwig, J.; Müller, T. E.; Thiel, O. R. *Chem. Eur. J.* **1999**, *5*, 1306. (c) Utsunomiya, M.; Kuwano, R.; Kawatsura, M.; Hartwig, J. F. *J. Am. Chem. Soc.* **2003**, *125*, 5608. (d) Jiménez, M. V.; Pérez-Torrente, J. J.; Bartolomé, M. I.; Lahoz, F. J.; Oro, L. A. *Chem. Commun.* **2010**, 46, 5322. (e) Jiménez, M. V.; Bartolomé, M. I.; Pérez-Torrente, J. J.; Lahoz, F. J.; Oro, L. A. *ChemCatChem* **2012**, *4*, 1298. (f) Jiménez, M. V.; Bartolomé, M. I.; Pérez-Torrente, J. J.; Gómez, D.; Modrego, F. J.; Oro, L. A. *ChemCatChem* **2013**, *5*, 263.
- (5) (a) Lu, J.; Jin, H.; Liu, H.; Jiang, Y.; Fu, H. *Org. Lett.* **2011**, *13*, 3694. (b) Liwosz, T. W.; Chemler, S. R. *Chem. Eur. J.* **2013**, *19*, 12771. (c) Xiong, P.; Xu, F.; Qian, X.-Y.; Yohannes, Y.; Song, J.; Lu, X.; Xu, H.-C. *Chem. Eur. J.* **2016**, *22*, 4379.
- (6) Ru: (a) Arockian, P. B.; Bruneau, C.; Dixneuf, P. H. *Chem. Rev.* **2012**, *112*, 5879. Ag: (b) Carrillo-Arcos, U. A.; Rojas-Ocampo, J.; Porcel, S. *Dalton Trans.* **2016**, 45, 479.
- (7) For recent examples of catalytic oxidative functionalization of alkenes without transition metals, see: (a) Trenner, J.; Depken, C.; Weber, T.; Breder, A. *Angew. Chem. Int. Ed.* **2013**, *52*, 8952. (b) Kawamata, Y.; Hashimoto, T.; Maruoka, K. *J. Am. Chem. Soc.* **2016**, *138*, 5206. (c) Zhang, G.; Hu, X.; Chiang, C.-W.; Yi, H.; Pei, P.; Singh, A. K.; Lei, A. *J. Am. Chem. Soc.* **2016**, *138*, 12037. (d) Yi, H.; Niu, L.; Song, C.; Li, Y.; Dou, B.; Singh, A. K.; Lei, A. *Angew. Chem. Int. Ed.* **2017**, *56*, 1120.
- (8) For recent reviews, see: (a) Huang, L.; Arndt, M.; Gooßen, K.; Heydt, H.; Gooßen, L. K. *Chem. Rev.* **2015**, *115*, 2596. (b) Patil, N. T.; Kavthe, R. D.; Shinde, V. S. *Tetrahedron* **2012**, *68*, 8079. (c) Hesp, K. D.; Stradiotto, M. *ChemCatChem* **2010**, *2*, 1192.
- (9) (a) Nagamoto, M.; Nishimura, T. *Chem. Commun.* **2015**, 51, 13466. (b) Nagamoto, M.; Yanagi, T.; Nishimura, T.; Yorimitsu, H. *Org. Lett.* **2016**, *18*, 4474.
- (10) (a) Dorta, R.; Egli, P.; Zürcher, F.; Togni, A. *J. Am. Chem. Soc.* **1997**, *119*, 10857. (b) Zhou, J.; Hartwig, J. F. *J. Am. Chem. Soc.* **2008**, *130*, 12220. (c) Hesp, K. D.; Tobisch, S.; Stradiotto, M. *J. Am. Chem. Soc.* **2010**, *132*, 413. (d) Pan, S.; Endo, K.; Shibata, T. *Org. Lett.* **2012**, *14*, 780. (e) Sevov, C. S.; Zhou, J.; Hartwig, J. F. *J. Am. Chem. Soc.* **2012**, *134*, 11960. (f) Sevov, C. S.; Hartwig, J. F. *J. Am. Chem. Soc.* **2013**, *135*, 9303. (g) Sevov, C. S.; Zhou, J.; Hartwig, J. F. *J. Am. Chem. Soc.* **2014**, *136*, 3200.
- (11) (a) Cheng, C.; Simmons, E. M.; Hartwig, J. F. *Angew. Chem. Int. Ed.* **2013**, *52*, 8984. (b) Li, Q.; Driess, M.; Hartwig, J. F. *Angew. Chem. Int. Ed.* **2014**, *53*, 8471. (c) Cheng, C.; Hartwig, J. F. *J. Am. Chem. Soc.* **2015**, *137*, 592. (d) Murai, M.; Takami, K.; Takai, K. *Chem. Eur. J.* **2015**, *21*, 4566. (e) Murai, M.; Takami, K.; Takeshima, H.; Takai, K. *Org. Lett.* **2015**, *17*, 1798.
- (12) Yamagata, T.; Tadaoka, H.; Nagata, M.; Hirao, T.; Kataoka, Y.; Ratovelomanana-Vidal, V.; Genet, J. P.; Mashima, K. *Organometallics* **2006**, *25*, 2505.
- (13) Hanley, P. S.; Hartwig, J. F. *Angew. Chem. Int. Ed.* **2013**, *52*, 8510.
- (14) Uson, R.; Oro, L. A.; Cabeza, J. A. *Inorg. Synth.* **1985**, *23*, 126.
- (15) Green, L. M.; Meek, D. W. *Organometallics* **1989**, *8*, 659.
- (16) Nicolai, S.; Piemontesi, C.; Waser, J. *Angew. Chem. Int. Ed.* **2011**, *50*, 4680.
- (17) Takeuchi, R.; Ue, N.; Tanabe, K.; Yamashita, K.; Shiga, N. *J. Am. Chem. Soc.* **2001**, *123*, 9525.
- (18) Barczak, N. T.; Jarvo, E. R. *Chem. Eur. J.* **2011**, *17*, 12912.
- (19) Innitzer, A.; Brecker, L.; Mulzer, J. *Org. Lett.* **2007**, *9*, 4431.